On the verge of something great

Faron Pharmaceuticals is a Turku-based biopharmaceutical company, who develop treatments for medical conditions with unmet needs. Traumakine®, a drug developed by the Company for treatment of Acute Respiratory Distress Syndrome, is currently on the homestretch having entered decisive Phase III clinical trials. So far the results have been excellent: in a study conducted in Great Britain, Traumakine reduced the patient mortality by 81% compared to the control cohort.

On the verge of something great

Faron Pharmaceuticals is a Turku-based biopharmaceutical company, who develop treatments for medical conditions with unmet needs. Traumakine®, a drug developed by the Company for treatment of Acute Respiratory Distress Syndrome, is currently on the homestretch having entered decisive Phase III clinical trials. So far the results have been excellent: in a study conducted in Great Britain, Traumakine reduced the patient mortality by 81% compared to the control cohort.

The CEO of Faron Pharmaceuticals, Markku Jalkanen, is one of the pioneers of Finnish biomedicine. We have had the privilege to work with him for over two decades. The work we have done for Faron includes, for example, company image as well as illustrations and animations, which help in illuminating how partially developed drugs work, also for non-professionals. Faron and their product development have attracted attention – that is easy to see just by glancing the direction of the Company’s share value development at London Stock Exchange.

’The foundation for long, loyal customer relationship is built on trust and mutual satisfaction.’

- Markku Jalkanen, CEO of Faron Pharmaceuticals

’The story must also evolve during the years, and if it manages to achieve its original goal after years have gone by, all the parties are satisfied.’

- Markku Jalkanen, CEO of Faron Pharmaceuticals